About VAHO
Founded in 1990, the Virginia Association of Hematologists and Oncologists (VAHO) is the largest oncology professional organization in the state. VAHO comprises a powerful community of oncologists, nurse practitioners, physician assistants, pharmacists, and other multidisciplinary care providers involved in the treatment of patients with cancer.
Events Calendar view all
Minimal Resident Disease (MRD) as an Endpoint in the Context of Multiple MyelomaThu | 2026 Spring MeetingThu |
Industry News view all
03/11/2026Bristol Myers Squibb Announces Positive Phase 3 Results from the SUCCESSOR-2 Study of Oral Mezigdomide in Relapsed or Refractory Multiple MyelomaBristol Myers Squibb announced positive Phase 3 results from the SUCCESSOR-2 clinical trial, evaluating the oral investigational drug mezigdomide in combination with carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma. The study met its primary endpoint, showing the combination significantly improved progression-free survival compared with standard therapy alone, meaning patients experienced a longer period before their disease worsened. Researchers reported a safety profile consistent with previous studies and plan to present more detailed results at an upcoming medical meeting. |
12/11/2025Virginia’s Prescription Drug Affordability Board needs guardrails to protect patient accessA recent commentary in the Virginia Mercury from Dr. Rich Ingram, VAHO President, highlights ongoing discussions around establishing a Prescription Drug Affordability Board (PDAB) in Virginia to address high prescription drug costs. While the goal of improving affordability is widely supported, the article emphasizes the importance of including safeguards—particularly if the board is authorized to set upper payment limits on certain medications. Without careful consideration of drug acquisition and administration costs, these limits could unintentionally make it difficult for providers to offer some treatments, particularly high-cost specialty medications such as those used in oncology. Policymakers are encouraged to ensure any affordability measures include protections that maintain patient access to needed therapies. |
11/21/2025FDA approves (Zepzelca) lurbinectedin in combination with atezolizumab or atezolizumab and hyaluronidase-tqjs for extensive-stage small cell lung cancerOn October 2, 2025, the Food and Drug Administration approved lurbinectedin (Zepzelca, Jazz Pharmaceuticals, Inc.) in combination with atezolizumab (Tecentriq, Genentech Inc.) or atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza, Genentech Inc.) for the maintenance treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease has not progressed after first-line induction therapy with atezolizumab or atezolizumab and hyaluronidase-tqjs, carboplatin, and etoposide. Full prescribing information for Zepzelca, Tecentriq, and Tecentriq Hybreza will be posted on Drugs@FDA. |
